Quantum Biopharma (NASDAQ:QNTM) Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen lowered shares of Quantum Biopharma (NASDAQ:QNTM) from a sell rating to a strong sell rating in a research note issued to investors on Saturday morning.

Separately, Weiss Ratings lowered Quantum Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, May 28th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Quantum Biopharma presently has an average rating of “Sell”.

Quantum Biopharma Price Performance

Shares of QNTM opened at $3.04 on Friday. Quantum Biopharma has a 1 year low of $2.07 and a 1 year high of $31.91. The stock’s fifty day moving average price is $4.73 and its two-hundred day moving average price is $4.55. The firm has a market cap of $19.46 million, a PE ratio of -0.37 and a beta of 0.43.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of QNTM. Virtu Financial LLC bought a new stake in Quantum Biopharma during the 4th quarter valued at $76,000. Jane Street Group LLC purchased a new stake in shares of Quantum Biopharma during the fourth quarter worth $80,000. Finally, Platform Technology Partners bought a new position in shares of Quantum Biopharma in the first quarter worth $199,000. 1.24% of the stock is owned by institutional investors.

About Quantum Biopharma

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.